Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
InsomniaGeneralized Anxiety Disorder
Interventions
DRUG

Eszopiclone (Lunesta)

Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime

Trial Locations (64)

Unknown

Birmingham

Mesa

Scottsdale

Irvine

La Mesa

National City

Oceanside

Orange

Pasadena

Redlands

Riverside

San Diego

Farmington

Washington D.C.

Coral Springs

Fort Lauderdale

Gainesville

Jacksonville

Orlando

Pembroke Pines

St. Petersburg

Atlanta

Augusta

Smyrna

Northfield

Indianapolis

Owensboro

Baltimore

Rockville

Braintree

Brighton

Brockton

Cambridge

Watertown

St Louis

Kenilworth

Piscataway

Brooklyn

Lawrence

New York

Durham

Raleigh

Winston-Salem

Bismarck

Beachwood

Cincinnati

Dayton

Middleburg Heights

Eugene

Portland

Salem

Moon Township

Philadelphia

Scotland

Columbia

Memphis

Austin

Houston

Richardson

San Antonio

Wichita Falls

Falls Church

Richmond

Middleton

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00235508 - Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter